Chalopin, T., Hulin, C., Royer, B., Bastie, J.-N., Bobin, A., Merzoug, K. B., Macro, M., Karlin, L., Jacquet, C., Mohty, M., Frenzel, L., Sonntag, C., Fontan, J., Rigaudeau, S., Roussel, M., Sanhes, L., Chaoui, D., Vincent, L., Orfeuvre, H., Bouketouche, M., Garlantezec, R., Decaux, O. and Perrot, A. (2020) “Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2025.287954.